Evidence map›Paper›PMID 29904126›Full record

Trial reportScientific reports2018

Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial.

Mark Ng Tang Fui, Rudolf Hoermann, Brendan Nolan, Michelle Clarke, Jeffrey D Zajac, Mathis Grossmann

Open access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Testosterone replacement in men with sexual dysfunction.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mark Ng Tang FuiDepartment of Medicine Austin Health, University of Melbourne, Heidelberg, Australia.
Rudolf HoermannDepartment of Medicine Austin Health, University of Melbourne, Heidelberg, Australia.
Brendan NolanDepartment of Endocrinology, Austin Health, Heidelberg, Australia.
Michelle ClarkeDepartment of Medicine Austin Health, University of Melbourne, Heidelberg, Australia.
Jeffrey D ZajacDepartment of Medicine Austin Health, University of Melbourne, Heidelberg, Australia.
Mathis GrossmannDepartment of Medicine Austin Health, University of Melbourne, Heidelberg, Australia. mathisg@unimelb.edu.au.
Austin Health · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the effect of testosterone treatment on bone remodelling and density in dieting obese men, 100 obese men aged 53 years (interquartile range 47-60) with a total testosterone level <12 nmol/L receiving 10 weeks of a very low energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of intramuscular testosterone undecanoate (n = 49, cases) or matching placebo (n = 51, controls). Pre-specified outcomes were between-group differences (mean adjusted difference, MAD) in serum c-telopeptide (CTx), N-terminal propeptide of type 1 procollagen (P1NP) and bone mineral density (BMD). At trial end, CTx was significantly reduced in men receiving testosterone compared to placebo, MAD -66 ng/L (95% CI -113, -18), p = 0.018, and this was apparent already after the 10 week VLED phase, MAD -63 ng/L (95% CI -108, -18), p = 0.018. P1NP was marginally increased after VLED, MAD +4.2 ug/L (95% CI -0.01, +8.4), p = 0.05 but lower at study end, MAD -5.6 ug/L (95% CI -10.1, -1.1), p = 0.03. No significant changes in sclerostin, lumbar spine BMD or femoral BMD were seen. We conclude that in obese men with low testosterone levels undergoing weight loss, bone remodelling markers are modulated in a way that may have favourable effects on bone mass.

Indexed as

Caloric RestrictionFemurLumbar VertebraeObesityAdaptor Proteins, Signal TransducingBone DensityBone Morphogenetic ProteinsGenetic MarkersHumansMaleMiddle AgedTestosteroneAdaptor Proteins, Signal TransducingBone Morphogenetic ProteinsGenetic MarkersSOST protein, humanTestosteronetestosterone undecanoate

Identifiers

PMID29904126
PMCPMC6002535
OpenAlexW2806513157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.